Ceregene, Inc.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

98 documents for Ceregene, Inc.

- Ceregene Inc.
Ceregene Inc. has announced the promotion of Raymond Bartus to the positions of executive vice president of clinical and preclinical research and deve...
- San Diego Business Journal
- December 17, 2007
- Michael J. Fox Foundation Awards $1.9 Million to Support Ceregene Phase Ii Gene Therapy Clinical Trial ; Funding Follows On Promising Early Results of Phase I Tria
To: National Desk, Health and Medical Reporter Contacts: Holly Barkhymer, 212-509-0995 ext. 242, or hbarkhymer@michaeljfox.orgof the Michael J. Fox Foundation, or Jeffrey M. Ostrove, 858-458-8808, or jostrove@ceregene.comof Ceregene Inc. NEW YORK, Oct. 10 /U.S. Newswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $1.9 million to support Ceregene Inc.'s Phase II study of CERE-120. This novel gene therapy product, which uses a vector to deliver neurturin, a potent nervous system trophic factor, has shown potential in preclinical studies to slow or stop Parkinson's disease progression. The funding follows on the announcement of promising early results from Ceregene's open-label Phase I trial of CERE-120, which also received Foundation support.
- U.S. Newswire
- October 10, 2006
- Michael J. Fox Foundation Announces Funding for Ceregene Phase-1 Gene Therapy Clinical Trial
NEW YORK, Nov. 28 /U.S. Newswire/ -- The Michael J. Fox Foundation for Parkinsonbs Research (MJFF) today announced a three- year grant of approximately $740,000 to Ceregene, Inc., a San Diego- based biotechnology company. The grant will help fund Ceregenebs Phase I clinical study of CERE-120, a novel gene therapy product that has shown potential in pre-clinical testing to slow or stop the progression of Parkinsonbs disease by using a vector to deliver neurturin, a potent nervous system growth factor. While the primary goal of any Phase I clinical study is to demonstrate safety, Ceregene will also measure the efficacy of CERE- 120 through brain imaging studies and standardized Parkinsonbs tests. MJFF support will significantly enhance the speed and depth of this data collection, allowing...
- U.S. Newswire
- November 28, 2005

- Reportlinker Adds World Growth Factors (Blood and Tissue) Market Report.
...The report profiles 90 companies including many key and niche players worldwide such as Amgen..., Inc., Alseres Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc., G...
- Business Wire
- March 24, 2009
- Research and Markets: Neurodegenerative Drugs: Global Strategic Business Report - Alzheimers Disease, Parkinsons Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others.
.... The report profiles 165 companies including many key and niche players such as Amarin Corporat...-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lill...
- Business Wire
- May 19, 2010
- BIO Opens Nominations For 2011 Biotech Humanitarian Award.
... and Chairman, Board of Directors, Ceregene, Inc. The Award and a prize of $10,000 will be pre...
- Business Wire
- March 07, 2011
- Key Challenges and Issues facing the World Growth Factors (Blood And Tissue) Market.
...The report profiles 90 companies including many key and niche players worldwide such as Amgen..., Inc., Alseres Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc., G...
- Business Wire
- January 08, 2009
- BioSante Pharmaceuticals and Cell Genesys Announce Completion of Merger.
...-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CE... 16 percent equity ownership position in Ceregene, Inc., a former subsidiary of Cell Genesys which i...
- Business Wire
- October 14, 2009
- Michael J. Fox Foundation Awards $4.6 Million to Help Advance Neurotrophic Factors As Transformative Parkinson's Treatments
NEW YORK, June 22 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced $4.6 million in awards to support two promising studies of neurotrophic factor therapies for Parkinson's disease. The projects, funded under a directed LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative, bring together leading investigators to build on the knowledge and experience gained from previous trials of neurotrophic factors to help speed this avenue of research toward better treatments for people living with PD. Neurotrophic factors (also known as trophic factors or growth factors) are specialized proteins that protect and nourish neurons in the brain, including the dopamine neurons that die in Parkinson's disease. Preclinical studies and several...

... awardees, the biopharmaceutical company Ceregene, Inc. will be conducting a Phase 2 clinical study ...
- U.S. Newswire
- June 22, 2010
- BIO Elects New Officers, Welcomes Nine New Board Members.
... Chair of the Health Section* Chairman, Ceregene, Inc. Mark Skaletsky, Treasurer* Chairman, Neuroph...
- Business Wire
- May 03, 2010